Predictive Oncology Announces Progress With FluGen In the Development Of First-Of-Its-Kind Intranasal Flu Vaccine, As Part Of A $6.2M Phase 2B Grant Awarded By The U.S. DOD
Portfolio Pulse from Benzinga Newsdesk
Predictive Oncology Inc. (NASDAQ:POAI) collaborates with FluGen on developing an intranasal flu vaccine, funded by a $6.2M Phase 2B grant from the U.S. Department of Defense. The project aims to create a stable, soluble vaccine for global distribution, leveraging Predictive Oncology's biologics capabilities and AI-driven drug discovery expertise.
April 30, 2024 | 8:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Predictive Oncology's collaboration with FluGen on a novel intranasal flu vaccine, supported by a significant DoD grant, highlights its biologics and AI-driven drug discovery strengths.
The collaboration with FluGen, backed by a substantial DoD grant, positions Predictive Oncology favorably in the biotech space, potentially enhancing its market value and investor interest. The project's success could lead to increased revenues and further partnerships, positively impacting POAI's stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100